Professional Documents
Culture Documents
Notice: Program Exclusions List
Notice: Program Exclusions List
Notice: Program Exclusions List
assign a numerical score to each Governments,’’ or OMB Circular A–122 VII. Agency Contact(s)
application, and to determine the ‘‘Non-Profit Organization’’; and
likelihood of its success. The comments (d) OMB Circular A–133 ‘‘Audits of Division of Epidemiology and Disease
from the ORC will be advisory only. States, Local Governments, and Non- Prevention, Indian Health Service,
Profit Organizations.’’ Selina Keryte Project Officer
3. Result of the Review (e) A–102 Grants and Cooperative (selina.keryte@ihs.gov), 5300 Homestead
The results of the objective review are agreements with State and Local Road, NE., Albuquerque, NM 87110,
forwarded to the Director, Office of Governments. Phone: (505) 248–4132. Fax: (505) 248–
Public Health Support (OPHS) for final (f) A–110 ‘‘Uniform Administrative 4393. Donald Reece
review and considerations. The OPHS Requirements for Grants and Other (donald.reece@ihs.gov), James Cheek,
Director will make recommendations for Agreements with Institutions of Higher M.D. (james.cheek@ihs.gov), Division of
approval and funding to the IHS Education, Hospitals, and Other Non- Grants Operations, Indian Health
Director who will then make the final Profit Organization. All Federal-wide Service, Twinbrook Metro Plaza, Suite
decision on all applications, within public policies apply to IHS grants with 360, 12300 Twinbrook Parkway,
approximately 30 days; applicants will the exception of Lobbying and Rockville, Maryland 20852.
be notified in writing of disapproval. A Discrimination.’’ Dated: March 9, 2006.
brief explanation of the reasons why the 3. Reporting Requirements Robert G. McSwain,
application was not approved will be Deputy Director, Indian Health Service.
provided along with the name of the (a) Semi-annual and annual program
progress reports are required. These [FR Doc. 06–2538 Filed 3–15–06; 8:45 am]
IHS official to contact if more
information is desired. reports will be no more than 10 pages BILLING CODE 4165–16–M
PROGRAM-RELATED CONVICTIONS
wwhite on PROD1PC61 with NOTICES
VerDate Aug<31>2005 15:48 Mar 15, 2006 Jkt 208001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\16MRN1.SGM 16MRN1
Federal Register / Vol. 71, No. 51 / Thursday, March 16, 2006 / Notices 13617
VerDate Aug<31>2005 15:48 Mar 15, 2006 Jkt 208001 PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 E:\FR\FM\16MRN1.SGM 16MRN1
13618 Federal Register / Vol. 71, No. 51 / Thursday, March 16, 2006 / Notices
LICENSE REVOCATION/SUSPENSION/SURRENDERED
VerDate Aug<31>2005 15:48 Mar 15, 2006 Jkt 208001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 E:\FR\FM\16MRN1.SGM 16MRN1
Federal Register / Vol. 71, No. 51 / Thursday, March 16, 2006 / Notices 13619
VerDate Aug<31>2005 15:48 Mar 15, 2006 Jkt 208001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\16MRN1.SGM 16MRN1
13620 Federal Register / Vol. 71, No. 51 / Thursday, March 16, 2006 / Notices
FEDERAL/STATE EXCLUSION/SUSPENSION
VerDate Aug<31>2005 15:48 Mar 15, 2006 Jkt 208001 PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 E:\FR\FM\16MRN1.SGM 16MRN1
Federal Register / Vol. 71, No. 51 / Thursday, March 16, 2006 / Notices 13621
Confidential Disclosure Agreement will In addition to licensing, the expression of transfected cytokines via a
be required to receive copies of the technology is available for further codon optimized IL–15 vector.
development through collaborative Applications of this technology beyond
patent applications.
research opportunities with the cancer include the potential use of
inventors. cytokine expressing cells in treating
VerDate Aug<31>2005 15:48 Mar 15, 2006 Jkt 208001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\16MRN1.SGM 16MRN1